Hypocalcemia Management

Patient Assessment and Monitoring

Patients with chronic kidney disease (CKD) should have their 25-hydroxyvitamin D levels checked annually, as recommended by the National Kidney Foundation 1
Intensive monitoring of ionized calcium every 4-6 hours for the first 48-72 hours is recommended for patients with hypocalcemia, with monitoring frequency adjusted based on clinical status 2
Serum calcium and phosphorus levels should be measured at least every 3 months, with 25-hydroxyvitamin D levels checked annually if normal, and more frequently if deficient, as recommended by the American Journal of Kidney Diseases 2
PTH levels should be monitored every 6-12 months in CKD stage 4, as suggested by the Kidney International guidelines 3

Total elemental calcium intake (dietary + supplements) should be limited to 2,000 mg/day, with further limitation needed for dialysis patients, as recommended by the American Journal of Kidney Diseases and the National Kidney Foundation 1, 2, 4
IV calcium gluconate infusion at 1-2 mg elemental calcium per kg body weight per hour should be initiated if ionized calcium falls below 0.9 mmol/L, with doses adjusted based on clinical response 2
Oral therapy with calcium carbonate 1-2 g three times daily plus calcitriol up to 2 μg/day is recommended when oral intake is possible, with doses adjusted based on serum calcium levels 2
Calcium salts such as calcium carbonate should be provided for patients with hypocalcemia, with total elemental calcium intake not exceeding 2,000 mg/day, as recommended by the American Journal of Kidney Diseases and other sources 2, 4

Vitamin D levels should be checked and active vitamin D sterol considered if vitamin D deficiency doesn't respond to ergocalciferol, as recommended by the National Kidney Foundation 2
Target 25-hydroxyvitamin D levels should be greater than 20-30 ng/mL, according to the Nature Reviews Nephrology guideline, and greater than 30 ng/mL as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 5, 6
Vitamin D supplementation with ergocalciferol should be initiated if 25-hydroxyvitamin D is <30 ng/mL, with active vitamin D sterol therapy considered for patients with persistent elevated PTH despite vitamin D repletion, as recommended by the American Journal of Kidney Diseases 2

Patients with CKD may require lower calcium doses to prevent vascular calcification, with serum corrected total calcium maintained within the normal range and calcium-phosphorus product kept below 55 mg²/dL, as recommended by the American Journal of Kidney Diseases 1, 2
Serum phosphorus should be controlled within target range (maintain <4.6 mg/dL in CKD stage 4), with phosphate binder dose adjusted or added if phosphorus exceeds 4.6 mg/dL while on vitamin D therapy, as recommended by the American Journal of Kidney Diseases 2
Medications that can cause hypocalcemia, such as bisphosphonates, proton pump inhibitors, and loop diuretics, should be discontinued or modified if possible, with oral calcium supplementation and vitamin D supplementation provided for chronic management, as recommended by the American Journal of Kidney Diseases and other sources 7, 2

Potential complications of hypocalcemia treatment include overcorrection leading to hypercalcemia, renal calculi formation, and renal failure, as well as rare but serious complications such as calcinosis cutis and tissue necrosis with extravasation of IV calcium, as reported by various sources 8, 9, 7
Calcium chloride should be administered by slow push for cardiac arrest, and infused over 30-60 minutes for other indications, with monitoring of heart rate and cessation if symptomatic bradycardia occurs, as recommended by the Pediatrics journal and other sources 7